Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.60 |
| ▸ | KDR | P35968 | 7/20 | 0.58 |
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22769719 | 0.88 | RET (0.62) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL31441113 | 0.88 | RET (0.62) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL21246971 | 0.88 | RET (0.57) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL21246991 | 0.87 | RET (0.62) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL21750982 | 0.84 | KDR (0.57) | RETKDREGFR | |
| SCHEMBL23770980 | 0.83 | RET (0.57) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL23749286 | 0.83 | RET (0.62) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL21265689 | 0.83 | RET (0.58) | RETKDRRAF1BRAFEGFR | |
| SCHEMBL21246957 | 0.80 | RET (0.61) | RETKDREGFR | |
| SCHEMBL21262659 | 0.80 | RET (0.79) | RETKDRRAF1BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-11407760-B2 | Dioxinoquinoline compounds, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-08-09 | — | — | US | disclosed |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2020-12-24 | — | — | US | disclosed |
| EP-3750893-A1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407760-B2 | Dioxinoquinoline compounds, preparation method and uses thereof | KDR, MET, ABL1 | RET 7/4885KDR 1/4885RAF1 76/4885 |
| US-20200399285-A1 | DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF | KDR, MET, ABL1 | RET 7/4885KDR 1/4885RAF1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.